Cara Therapeutics
Shelton
About Cara Therapeutics
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $517.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2023)
- Ticker: nasdaq:CARA
- Website: caratherapeutics.com
- Phone: +1 203 567 1503
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cara-therapeutics-118679 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.